Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2014; 6(4): 497-504
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.497
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.497
Ability of bone graft substitutes to support the osteoprogenitor cells: An in-vitro study
Ziad Dahabreh, Michalis Panteli, Ippokratis Pountos, Peter V Giannoudis, Academic Department of Trauma and Orthopaedics, School of Medicine, University of Leeds, LS1 3EX Leeds, United Kingdom
Mark Howard, Smith and Nephew Research Centre, YO10 5DF York, United Kingdom
Peter Campbell, Trauma and Orthopaedics Surgery, York Teaching Hospitals, YO31 8HE York, United Kingdom
Author contributions: All the authors solely contributed to this paper.
Supported by Educational grant by Smith and Nephew
Correspondence to: Peter V Giannoudis, BSc, MB, MD, FRCS, Professor, Academic Department of Trauma and Orthopaedics, School of Medicine, University of Leeds, Great George Street, LS1 3EX Leeds, United Kingdom. pgiannoudi@aol.com
Telephone: +44-113-3922750 Fax: +44-113-3923290
Received: May 20, 2014
Revised: August 20, 2014
Accepted: August 30, 2014
Published online: September 26, 2014
Revised: August 20, 2014
Accepted: August 30, 2014
Published online: September 26, 2014
Core Tip
Core tip: Various commercially available bone graft substitutes (BGS) exist today and are used for the restoration of bone defects resulting from traumatic injury, tumor resection and congenital or degenerative diseases. Such BGS should pose osteoinductive and osteoconductive properties and support cell response to the osteogenic signalling. This study evaluated seven commercially available BGS in terms of osteoprogenitor cell adherence, proliferation and osteogenic differentiation. β-tricalcium phosphate was found to have the most favourable effect on cell viability and allow for their subsequent proliferation and differentiation.